Article ; Online: Phase 1 Open-Label Dose Escalation Trial for the Development of a Human Bacillus Calmette-Guérin Challenge Model for Assessment of Tuberculosis Immunity In Vivo.
The Journal of infectious diseases
2023 Volume 229, Issue 5, Page(s) 1498–1508
Abstract: Background: A controlled human infection model for assessing tuberculosis (TB) immunity can accelerate new vaccine development.: Methods: In this phase 1 dose escalation trial, 92 healthy adults received a single intradermal injection of 2 × 106 to ... ...
| Abstract | Background: A controlled human infection model for assessing tuberculosis (TB) immunity can accelerate new vaccine development. Methods: In this phase 1 dose escalation trial, 92 healthy adults received a single intradermal injection of 2 × 106 to 16 × 106 colony-forming units of Bacillus Calmette-Guérin (BCG). The primary endpoints were safety and BCG shedding as measured by quantitative polymerase chain reaction, colony-forming unit plating, and MGIT BACTEC culture. Results: Doses up to 8 × 106 were safe, and there was evidence for increased BCG shedding with dose escalation. The MGIT time-to-positivity assay was the most consistent and precise measure of shedding. Power analyses indicated that 10% differences in MGIT time to positivity (area under the curve) could be detected in small cohorts (n = 30). Potential biomarkers of mycobacterial immunity were identified that correlated with shedding. Transcriptomic analysis uncovered dose- and time-dependent effects of BCG challenge and identified a putative transcriptional TB protective signature. Furthermore, we identified immunologic and transcriptomal differences that could represent an immune component underlying the observed higher rate of TB disease incidence in males. Conclusions: The safety, reactogenicity, and immunogenicity profiles indicate that this BCG human challenge model is feasible for assessing in vivo TB immunity and could facilitate the vaccine development process. Clinical trials registration: NCT01868464 (ClinicalTrials.gov). |
|---|---|
| MeSH term(s) | Humans ; Male ; Adult ; Female ; BCG Vaccine/immunology ; BCG Vaccine/administration & dosage ; Tuberculosis/prevention & control ; Tuberculosis/immunology ; Young Adult ; Mycobacterium bovis/immunology ; Middle Aged ; Mycobacterium tuberculosis/immunology ; Injections, Intradermal ; Adolescent ; Dose-Response Relationship, Immunologic |
| Language | English |
| Publishing date | 2023-11-29 |
| Publishing country | United States |
| Document type | Journal Article ; Clinical Trial, Phase I |
| ZDB-ID | 3019-3 |
| ISSN | 1537-6613 ; 0022-1899 |
| ISSN (online) | 1537-6613 |
| ISSN | 0022-1899 |
| DOI | 10.1093/infdis/jiad441 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Uh II Zs.50: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
|||
| Zs.MO 445: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.